SCHEMBL24328360

SCHEMBL24328360

Cc1cccc2[nH]cc(C[C@H](O)C(=O)O)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.61
GPR84 Q9NQS5 1/20 0.58
ADRB3 P13945 1/20 0.51
ITGB2 P05107 2/20 0.47
ICAM1 P05362 2/20 0.47
ITGAL P20701 2/20 0.47
NR3C1 P04150 1/20 0.46
NR3C2 P08235 1/20 0.46
POLB P06746 4/20 0.46
MAPT P10636 4/20 0.46
KDM4E B2RXH2 3/20 0.46
RECQL P46063 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
APAF1 O14727 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
GAA P10253 2/20 0.44
ALDH1A1 P00352 1/20 0.44
THRB P10828 1/20 0.44
DNMT1 P26358 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28409195 1.00 SMN1; SMN2 (0.61) SMN1; SMN2GPR84ADRB3ITGB2ICAM1
SCHEMBL29406297 0.84 KMT2A (0.62) GPR84ADRB3ITGB2ICAM1ITGAL
SCHEMBL109838 0.84 KMT2A (0.62) GPR84ADRB3ITGB2ICAM1ITGAL
SCHEMBL21055747 0.84 KMT2A (0.62) GPR84ADRB3ITGB2ICAM1ITGAL
SCHEMBL29556951 0.84 KMT2A (0.62) GPR84ADRB3ITGB2ICAM1ITGAL
SCHEMBL109837 0.84 KMT2A (0.62) GPR84ADRB3ITGB2ICAM1ITGAL
SCHEMBL18028997 0.84 KMT2A (0.62) GPR84ADRB3ITGB2ICAM1ITGAL
SCHEMBL24328896 0.83 GPR84 (0.55) SMN1; SMN2GPR84ADRB3ITGB2ICAM1
SCHEMBL24328926 0.83 SMN1; SMN2 (0.61) SMN1; SMN2GPR84ADRB3ITGB2ICAM1
SCHEMBL24328922 0.83 SMN1; SMN2 (0.61) SMN1; SMN2GPR84ITGB2ICAM1ITGAL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
WO-2022078416-A1 NOVEL GLUTAMINE ANALOGS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399297-A1 Novel Glutamine Analogs GLUL, GATD3, GLS SMN1; SMN2 3812/4885GPR84 178/4885ADRB3 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.